Skip to main content
Top
Published in: BMC Psychiatry 1/2003

Open Access 01-12-2003 | Research article

Gross Domestic Product (GDP) and productivity of schizophrenia trials: an ecological study

Authors: Carina Moll, Ursula Gessler, Stephanie Bartsch, Hany George El-sayeh, Mark Fenton, Clive Elliott Adams

Published in: BMC Psychiatry | Issue 1/2003

Login to get access

Abstract

Background

The 5000 randomised controlled trials (RCTs) in the Cochrane Schizophrenia Group's database affords an opportunity to research for variables related to the differences between nations of their output of schizophrenia trials.

Methods

Ecological study – investigating the relationship between four economic/demographic variables and number of schizophrenia RCTs per country. The variable with closest correlation was used to predict the expected number of studies.

Results

GDP closely correlated with schizophrenia trial output, with 76% of the total variation about the Y explained by the regression line (r = 0.87, 95% CI 0.79 to 0.92, r2 = 0.76). Many countries have a strong tradition of schizophrenia trials, exceeding their predicted output. All nations with no identified trial output had GDPs that predicted zero trial activity. Several nations with relatively small GDPs are, nevertheless, highly productive of trials. Some wealthy countries seem either not to have produced the expected number of randomised trials or not to have disseminated them to the English-speaking world.

Conclusions

This hypothesis-generating study could not investigate causal relationships, but suggests, that for those seeking all relevant studies, expending effort searching the scientific literature of Germany, Italy, France, Brazil and Japan may be a good investment.
Appendix
Available only for authorised users
Literature
2.
go back to reference Adams CE, Duggan L, Wahlbeck K, White P: The Cochrane Schizophrenia Group. Schizophrenia Research. 1998, 33: 185-186. 10.1016/S0920-9964(98)00072-3.CrossRefPubMed Adams CE, Duggan L, Wahlbeck K, White P: The Cochrane Schizophrenia Group. Schizophrenia Research. 1998, 33: 185-186. 10.1016/S0920-9964(98)00072-3.CrossRefPubMed
7.
go back to reference Furukawa TA, Inada T, Adams CE, McGuire H, Inagaki A, Nozaki S: Are the Cochrane group registers comprehensive? A case study of Japanese psychiatry trials. BMC Psychiatry. 2002, 2: 6-10.1186/1471-244X-2-6.CrossRef Furukawa TA, Inada T, Adams CE, McGuire H, Inagaki A, Nozaki S: Are the Cochrane group registers comprehensive? A case study of Japanese psychiatry trials. BMC Psychiatry. 2002, 2: 6-10.1186/1471-244X-2-6.CrossRef
8.
go back to reference Inada T, Inagaki A, Otsuki N, Yoshio T: Psychotropic drugs: Evidence of the 20th century in Japan. 2000, Tokyo, Japan: Seiwa Shoten Inada T, Inagaki A, Otsuki N, Yoshio T: Psychotropic drugs: Evidence of the 20th century in Japan. 2000, Tokyo, Japan: Seiwa Shoten
9.
go back to reference Armitage P, Berry G: Statistical methods in medical research. 1994, Oxford, Boston: Blackwell Scientific Publications Armitage P, Berry G: Statistical methods in medical research. 1994, Oxford, Boston: Blackwell Scientific Publications
Metadata
Title
Gross Domestic Product (GDP) and productivity of schizophrenia trials: an ecological study
Authors
Carina Moll
Ursula Gessler
Stephanie Bartsch
Hany George El-sayeh
Mark Fenton
Clive Elliott Adams
Publication date
01-12-2003
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2003
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-3-18

Other articles of this Issue 1/2003

BMC Psychiatry 1/2003 Go to the issue